Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
16 Apr 24
10-K
2023 FY
Annual report
5 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Termination of a Material Definitive Agreement
28 Mar 24
8-K
Entry into a Material Definitive Agreement
27 Feb 24
8-K
Entry into a Material Definitive Agreement
22 Feb 24
8-K
Entry into a Material Definitive Agreement
7 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Nov 23
8-K
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
8 Nov 23
8-K
Regulation FD Disclosure
17 Oct 23
S-1/A
IPO registration (amended)
2 Oct 23
424B3
Prospectus supplement
29 Sep 23
8-K
Entry into a Material Definitive Agreement
28 Sep 23
EFFECT
Notice of effectiveness
8 Sep 23
POS AM
Prospectus update (post-effective amendment)
1 Sep 23
8-K
Results of Operations and Financial Condition
15 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Departure of Directors or Certain Officers
4 Aug 23
8-K
Regulation FD Disclosure
1 Aug 23
8-K
Entry into a Material Definitive Agreement
26 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
13 Jul 23
8-K
Departure of Directors or Certain Officers
26 Jun 23
S-1
IPO registration
13 Jun 23
ARS
2022 FY
Annual report to shareholders
2 Jun 23
DEF 14A
Definitive proxy
2 Jun 23
8-K
Departure of Directors or Certain Officers
19 May 23
PRE 14A
Preliminary proxy
15 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5 May 23
10-K
2022 FY
Annual report
2 May 23
8-K
Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing
24 Apr 23
NT 10-K
Notice of late annual filing
31 Mar 23
8-K
Regulation FD Disclosure
13 Feb 23
8-K
Departure of Directors or Certain Officers
20 Jan 23
8-K
Regulation FD Disclosure
10 Jan 23
EFFECT
Notice of effectiveness
6 Jan 23
CORRESP
Correspondence with SEC
3 Jan 23
Latest ownership filings
4
Wajdi Abdul-Ahad
4 Aug 22
4
Christopher L. Lotz
4 Aug 22
4
TARIQ ARSHAD
4 Aug 22
4
Ira E. Ritter
4 Aug 22
4
SIDNEY W EMERY JR
4 Aug 22
4
Kurt H Kruger
4 Aug 22
4
Richard A. David
4 Aug 22
4
Shishir K. Sinha
4 Aug 22
4
Michael S. Poirier
4 Aug 22
4
Matthew E Korenberg
4 Aug 22
4
AMY S. BROIDRICK
4 Aug 22
4
Michael S. Poirier
22 Jun 22
4
AMY S. BROIDRICK
15 Jun 22
SC 13G/A
ALPHA CAPITAL ANSTALT
27 May 22
SC 13G/A
SABBY MANAGEMENT, LLC
5 Jan 22
4
AMY S. BROIDRICK
10 Dec 21
4
TARIQ ARSHAD
10 Dec 21
SC 13G
SABBY MANAGEMENT, LLC
6 Dec 21
4
Kurt H Kruger
20 Aug 21
4
TARIQ ARSHAD
18 May 21
3
TARIQ ARSHAD
17 May 21
4
AMY S. BROIDRICK
26 Apr 21
4
Michael S. Poirier
21 Apr 21
4
Christopher L. Lotz
19 Apr 21
4
Kurt H Kruger
30 Dec 20
4
AMY S. BROIDRICK
29 Dec 20
4
SIDNEY W EMERY JR
8 Dec 20
3
SIDNEY W EMERY JR
7 Dec 20
4
Kurt H Kruger
23 Nov 20
4
AMY S. BROIDRICK
28 Aug 20
3
AMY S. BROIDRICK
28 Aug 20
4
Change in insider ownership
5 Aug 20
4
Ira E. Ritter
8 Jun 20
4
Richard A. David
8 Jun 20
4
Michael S. Poirier
8 Jun 20
4
Wajdi Abdul-Ahad
8 Jun 20
4
Kurt H Kruger
8 Jun 20
4
Shishir K. Sinha
8 Jun 20
4
Matthew E Korenberg
8 Jun 20
4
Christopher L. Lotz
8 Jun 20